Clinically benign tumors generally do not affect the patient’s life expectancy, while the survival of malignant tumors is related to the tumor stage, pathological typing, the patient’s comprehensive quality and the effect of comprehensive treatment, and can not be generalized.
Benign tumors, with relatively slow growth rate, are generally not characterized by metastasis. When the tumor is small, it can be observed regularly, but if the tumor increases in size and the corresponding symptoms appear, timely surgical treatment should be carried out, and the cure generally will not recur, and generally will not affect the patient’s life expectancy.
For malignant tumors, early intervention and treatment at an early stage, the vast majority of patients can avoid death caused by malignant tumors. If the malignant tumor is in the middle or late stage, it has a greater impact on the patient’s life expectancy, and if treatment is abandoned, the vast majority of patients are difficult to survive for more than half a year. If the overall quality of the patient’s body is high, active treatment can appropriately extend the patient’s survival period.
In addition, benign tumors in some special areas such as the cranial cavity may be transformed into malignant. Therefore, regardless of benign tumors or malignant tumors, it is recommended that patients go to the hospital in time for consultation and active treatment, so as not to affect the life expectancy.